Clinical Trials
12 trialsNCT07445048 2026-04-17
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 3 Recruiting
NCT05469178 2025-10-29
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
BerGenBio ASA
Phase 1/2 Terminated
NCT03184571 2025-09-25
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
BerGenBio ASA
Phase 2 Completed
NCT02424617 2025-02-26
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
BerGenBio ASA
Phase 1/2 Completed
NCT06469138 2025-01-29
8479217
BerGenBio ASA
Phase 1 Completed
NCT02488408 2024-12-19
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
BerGenBio ASA
Phase 1/2 Completed
NCT02922777 2024-02-21
Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT03965494 2024-02-08
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Terminated
NCT03649321 2023-11-09
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT03824080 2021-12-21
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
GWT-TUD GmbH
Phase 2 Completed
NCT03184558 2021-11-09
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
BerGenBio ASA
Phase 2 Terminated